Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
about
Physostigmine for Alzheimer's disease.Neurotransmitter replacement therapy in Alzheimer's disease.Current treatment and recent clinical research in Alzheimer's diseaseMultiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease.Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent.Clinical pharmacology and therapeutics.Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.Hormesis and medicine.Current perspectives on pharmacotherapy of Alzheimer's disease.Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.Effect of cholinergic signaling on neuronal cell bioenergetics.Interaction of basal forebrain cholinergic neurons with the glucocorticoid system in stress regulation and cognitive impairment.Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions.Critical review of clinical trials in senile dementia--II.Neurotransmitter deficits in Alzheimer's disease: criteria for significance.Biologic markers and neurochemical correlates of agitation and psychosis in dementia.Factor structure and reliability of the Alzheimer's Disease Assessment Scale in a multicenter trial with linopirdine.Effects of cholinergic enhancement on conditioning-related responses in human auditory cortex.Lithium-induced neurotoxicity at serum lithium levels within the therapeutic range.[Relations between specific neurochemical systems and memory: problems posed by dementia of the Alzheimer type]Treating a novel plasticity defect rescues episodic memory in Fragile X model mice.Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus.PET imaging in Alzheimer's disease.Canadian collaborative study of tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer's disease: effect on mood.Effects of physostigmine on stimulus encoding in a memory-scanning task.Development of memory-enhancing agents in the treatment of Alzheimer's disease.Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
P2860
Q33423337-C0AEC282-BF10-4EBE-BB21-1A4229A31898Q33921314-BBF33BE6-25BF-4FE1-B3AE-71DF89F75F37Q34067487-7254238E-3579-4731-AB82-7A76A582F5D6Q34147354-971EC4E7-F6D0-401B-B8F2-7F65873CC1BFQ35048154-11CBDF23-5659-428F-9CD5-D46CEB7AF4DFQ36031960-34CF9854-9558-4A23-A4E8-F2BECFEF3922Q36682367-F23B5977-8F25-41B4-84B9-942A357A850EQ36884943-F9C3A279-9303-432F-BCC7-5DE50A10E057Q37073096-912D9451-9AA7-445C-A6A1-7C2FCF0D4495Q37142421-5C631FC1-3116-465F-8A27-82BB3A738FAFQ37827489-2E9E0443-882C-4C0C-AD6F-585EEF4B41DAQ38262767-838B1AFD-F999-4D85-8658-2FFE29817A19Q38413032-076AFFD1-4EC8-48D2-B4B2-8F98A7493ACEQ38425466-693421A0-DC21-4F3E-A5C3-B374842CA003Q38596419-75019132-F586-461C-9007-79C2FCADE034Q38960486-284A0F62-14A6-4D0A-8B41-A33F3261F6FCQ39173624-7E63C0B0-3AAD-4082-B1FA-E5FE0DE54569Q40089993-0222BF03-A5B4-4913-AB2C-9A43A86ACDA5Q40945362-5D5D63A6-783F-40A6-8AE5-85BC03F9D928Q41036734-2B7DA908-3754-4FDE-A9CF-4FA7F7653B18Q42528576-B43136A6-34B8-4B22-AC50-C5A7C701D101Q42551159-C8962F80-E118-44E7-9B9E-154E5A485333Q42555682-5D39216F-020D-4962-871C-6EE588AB1E9BQ46229249-2E274476-C76C-46B6-AE34-FEFCF8E33B8DQ48250407-959A47BF-2188-4BAB-A458-BB0D0D416971Q51603028-8423D4F5-322F-4F1F-9D97-92C506EABA10Q52044679-15E9F61C-45CA-4468-A68D-F0241B65B370Q52066078-6B9093E0-0DC5-463F-A9DA-343B6A73ED03Q52081590-1C5ECB22-3431-4537-8B81-89DE7EE02DBFQ52128947-D947FDCE-07FB-4740-B28C-CDF42CB7B896Q52204857-EF086317-E86B-4D73-B505-343B26A72FC1
P2860
Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh-hant
name
Enhancement of memory processe ...... ose intravenous physostigmine.
@en
Enhancement of memory processe ...... ose intravenous physostigmine.
@nl
type
label
Enhancement of memory processe ...... ose intravenous physostigmine.
@en
Enhancement of memory processe ...... ose intravenous physostigmine.
@nl
prefLabel
Enhancement of memory processe ...... ose intravenous physostigmine.
@en
Enhancement of memory processe ...... ose intravenous physostigmine.
@nl
P356
P1476
Enhancement of memory processe ...... ose intravenous physostigmine.
@en
P2093
P304
P356
10.1176/AJP.139.11.1421
P407
P577
1982-11-01T00:00:00Z